Okay, there has been a mistake. Sorry, TE, you are probably right about Singapore investors funding Series B.
Leeroy posted a link
This article is about Series A funding. Leeroy posted it as breaking news (probably because the date shown in the article is the current date, not the article’s date), but this piece of news is, in fact, 2 years old (dates May,02, 2008) and it is listed on Histogen’s website:
This Series A was indeed funded by American investors, but the current funding round is Series B, and foum member ET could be right when he says this is being funded by Singapore investors.
Sorry, TE, at the time, I was not well informed about these “funding rounds” so I thought Series A was the latest one. I should have verified the date of the article.
» Link provided by Leeroy.Jenkins:
» Histogen Announces Initial Close of Series A Financing Round
» Histogen, Inc., a regenerative medicine company developing solutions based
» on the products of newborn fibroblasts, today announced the initial close
» of Series A financing at $5.35 million. The round was completed by private
» and corporate investors, including Secure Medical Inc., CellCeuticals
» Skin Care Inc., and Leonard H. Lavin, founder and Chairman Emeritus of the
» Alberto-Culver Company.
» These are all american investors.
» » It seems that US investors didn’t want to help. What a shame. Histogen
» » to go to Singapore for help. Thanks “TE” for the info.
» » # TE
» » 6/17/10 11:12 pm
» » Whoop – Histogen was subjected to a lawsuit for copyright infringement
» » (for a product that Histogen had not brought to market) no further news
» » been provided about the lawsuit (if anyone knows anything further I
» » love to hear it). The lawsuit did, however, result in a loss of funding
» » investors in the United States. Histogen then found some investors in
» » Singapore – and, as a precondition to the investment, are continuing
» » phase II trials there (Singapore). The advantage of the trials overseas
» » include a reduced time to come to market (no FDA approval required)
» » maintaining a strict adherence to trial standards that meet US criteria.
» » successful, Histogen will continue phase III in Asia and launch their
» » product in that market (except for Japan). I think Histogen is making
» » best of a difficult situation and, hopefully, we will hear some good
» » soon.